4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000139
CFO sold 300,000 shares at an average $41.58 ($12,473,272)
- CFO acquired 252,365 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Pulik Richard CFO | 2026-11-10 | Option exercise | +125,000 | $3.85 | $481,250 | 394,681 | D: show line 1 in the form |
| Pulik Richard CFO | 2026-11-10 | Sale | −125,000 | $41.20 | $5,150,000 | 269,681 | D: show line 2 in the form |
| Pulik Richard CFO | 2026-11-11 | Option exercise | +127,365 | $3.85 | $490,355 | 397,046 | D: show line 3 in the form |
| Pulik Richard CFO | 2026-11-11 | Sale | −45,195 | $41.47 | $1,874,237 | 351,851 | D: show line 4 in the form |
| Pulik Richard CFO | 2026-11-11 | Sale | −82,170 | $42.03 | $3,453,605 | 269,681 | D: show line 5 in the form |
| Pulik Richard CFO | 2026-11-11 | Sale | −47,635 | $41.89 | $1,995,430 | 222,046 | D: show line 6 in the form |
| Open-market sales · 300,000 sh · avg $41.58 · $12,473,272 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulik Richard CFO | 2026-11-10 | Option exercise · Stock Option (Right to Buy) | −125,000 | 615,000 | D: show line 7 in the form | |||||
| Pulik Richard CFO | 2026-11-11 | Option exercise · Stock Option (Right to Buy) | −127,365 | 487,635 | D: show line 8 in the form |
Loading xslF345X06/wk-form4_1794528063.xml…